Immunoglobulin E (IgE) mediated signaling pathway (IgE pathway)

The Immunoglobulin E (IgE) mediated signaling pathway is a central driver of Type I hypersensitivity reactions and allergic diseases. This pathway is initiated when allergen-specific B cells, under the influence of Th2 cytokines like IL-4 and IL-13, undergo class-switch recombination to produce IgE antibodies. These IgE molecules bind with high affinity to the FcεRI receptor on the surface of mast cells and basophils. Upon subsequent exposure to the specific allergen, the IgE-FcεRI complexes are cross-linked, triggering a signaling cascade that leads to the rapid release of inflammatory mediators such as histamine, leukotrienes, and proteases. (Source: NIH/NIAID, PubMed: 29307320). In chronic allergic conditions like asthma and atopic dermatitis, this pathway contributes to persistent tissue inflammation and airway hyperresponsiveness. Therapeutic intervention primarily focuses on interrupting the IgE-FcεRI interaction or depleting the IgE pool. Omalizumab, a monoclonal antibody, is the gold standard for this approach, as it sequesters free IgE and leads to the downregulation of FcεRI receptors on effector cells. Emerging therapies also target upstream drivers like TSLP or IL-4Rα, or downstream signaling components like Bruton's tyrosine kinase (BTK), to provide more comprehensive control of the allergic response. (Source: StatPearls, Journal of Allergy and Clinical Immunology: 141(1)).

Other names

Type I hypersensitivity pathwayIgE-FcεRI axisAllergen-specific Th2 responseAllergic cascadeIgE-mediated allergic response

Neutralization of circulating IgE to prevent binding to FcεRI; Downregulation of high-affinity IgE receptors on effector cells; Inhibition of IL-4/IL-13 signaling to prevent B-cell class switching to IgE; Inhibition of Bruton's tyrosine kinase (BTK) to block downstream signaling from FcεRI.